Cargando…
New disappearance of complicated atheromatous plaques on rechallenge with PD-1/PD-L1 axis blockade in non-small cell lung cancer patient: follow up of an unexpected event
Atherosclerosis is considered an irreversible process, with crucial contribution of inflammation and immune cells. Impact of cancer immunotherapy on a partly immune-driven disease, such as atherosclerosis, is poorly understood, but preclinical models suggest its worsening on programmed death/ligand-...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383634/ https://www.ncbi.nlm.nih.gov/pubmed/32782484 http://dx.doi.org/10.1177/1758835920913801 |
_version_ | 1783563460175462400 |
---|---|
author | Lamberti, Giuseppe Gelsomino, Francesco Brocchi, Stefano Poerio, Antonio Melotti, Barbara Sperandi, Francesca Gargiulo, Mauro Borghi, Claudio Fiorentino, Michelangelo Ardizzoni, Andrea |
author_facet | Lamberti, Giuseppe Gelsomino, Francesco Brocchi, Stefano Poerio, Antonio Melotti, Barbara Sperandi, Francesca Gargiulo, Mauro Borghi, Claudio Fiorentino, Michelangelo Ardizzoni, Andrea |
author_sort | Lamberti, Giuseppe |
collection | PubMed |
description | Atherosclerosis is considered an irreversible process, with crucial contribution of inflammation and immune cells. Impact of cancer immunotherapy on a partly immune-driven disease, such as atherosclerosis, is poorly understood, but preclinical models suggest its worsening on programmed death/ligand-1 (PD-1/PD-L1) inhibitors. In a previously reported cohort of 11 patients with non-small cell lung cancer (NSCLC) treated with nivolumab and pre-existing complicated atheromatous plaques, 3 patients had a dramatic radiologic reduction of aortic plaques while on nivolumab; of these 3, 2 died receiving no further treatment. The remaining patient was an 83-year-old woman with history of arterial hypertension and hypothyroidism who was diagnosed with locally advanced squamous NSCLC. At relapse, complicated aortic atheromatous plaques were demonstrated on scans. The patient was then treated with nivolumab obtaining stable disease at radiological assessment, which also demonstrated almost complete vanishing of aortic plaques. After relapse and interval treatment with chemotherapy, she experienced new development of aortic atheromatous plaques. At further relapse she received atezolizumab, which yielded disease response and new reduction in aortic plaques, until nearly complete resolution. The observation of a repeated improvement of atheromatous plaques on treatment with PD-1/PD-L1 inhibitors favors the protective role of T cells on atheromatous plaques that is impaired by PD-L1 expression by plaque-associated macrophages. Validation by independent and prospective observation is needed. |
format | Online Article Text |
id | pubmed-7383634 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-73836342020-08-10 New disappearance of complicated atheromatous plaques on rechallenge with PD-1/PD-L1 axis blockade in non-small cell lung cancer patient: follow up of an unexpected event Lamberti, Giuseppe Gelsomino, Francesco Brocchi, Stefano Poerio, Antonio Melotti, Barbara Sperandi, Francesca Gargiulo, Mauro Borghi, Claudio Fiorentino, Michelangelo Ardizzoni, Andrea Ther Adv Med Oncol Case Report Atherosclerosis is considered an irreversible process, with crucial contribution of inflammation and immune cells. Impact of cancer immunotherapy on a partly immune-driven disease, such as atherosclerosis, is poorly understood, but preclinical models suggest its worsening on programmed death/ligand-1 (PD-1/PD-L1) inhibitors. In a previously reported cohort of 11 patients with non-small cell lung cancer (NSCLC) treated with nivolumab and pre-existing complicated atheromatous plaques, 3 patients had a dramatic radiologic reduction of aortic plaques while on nivolumab; of these 3, 2 died receiving no further treatment. The remaining patient was an 83-year-old woman with history of arterial hypertension and hypothyroidism who was diagnosed with locally advanced squamous NSCLC. At relapse, complicated aortic atheromatous plaques were demonstrated on scans. The patient was then treated with nivolumab obtaining stable disease at radiological assessment, which also demonstrated almost complete vanishing of aortic plaques. After relapse and interval treatment with chemotherapy, she experienced new development of aortic atheromatous plaques. At further relapse she received atezolizumab, which yielded disease response and new reduction in aortic plaques, until nearly complete resolution. The observation of a repeated improvement of atheromatous plaques on treatment with PD-1/PD-L1 inhibitors favors the protective role of T cells on atheromatous plaques that is impaired by PD-L1 expression by plaque-associated macrophages. Validation by independent and prospective observation is needed. SAGE Publications 2020-07-24 /pmc/articles/PMC7383634/ /pubmed/32782484 http://dx.doi.org/10.1177/1758835920913801 Text en © The Author(s), 2020 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Case Report Lamberti, Giuseppe Gelsomino, Francesco Brocchi, Stefano Poerio, Antonio Melotti, Barbara Sperandi, Francesca Gargiulo, Mauro Borghi, Claudio Fiorentino, Michelangelo Ardizzoni, Andrea New disappearance of complicated atheromatous plaques on rechallenge with PD-1/PD-L1 axis blockade in non-small cell lung cancer patient: follow up of an unexpected event |
title | New disappearance of complicated atheromatous plaques on rechallenge with PD-1/PD-L1 axis blockade in non-small cell lung cancer patient: follow up of an unexpected event |
title_full | New disappearance of complicated atheromatous plaques on rechallenge with PD-1/PD-L1 axis blockade in non-small cell lung cancer patient: follow up of an unexpected event |
title_fullStr | New disappearance of complicated atheromatous plaques on rechallenge with PD-1/PD-L1 axis blockade in non-small cell lung cancer patient: follow up of an unexpected event |
title_full_unstemmed | New disappearance of complicated atheromatous plaques on rechallenge with PD-1/PD-L1 axis blockade in non-small cell lung cancer patient: follow up of an unexpected event |
title_short | New disappearance of complicated atheromatous plaques on rechallenge with PD-1/PD-L1 axis blockade in non-small cell lung cancer patient: follow up of an unexpected event |
title_sort | new disappearance of complicated atheromatous plaques on rechallenge with pd-1/pd-l1 axis blockade in non-small cell lung cancer patient: follow up of an unexpected event |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383634/ https://www.ncbi.nlm.nih.gov/pubmed/32782484 http://dx.doi.org/10.1177/1758835920913801 |
work_keys_str_mv | AT lambertigiuseppe newdisappearanceofcomplicatedatheromatousplaquesonrechallengewithpd1pdl1axisblockadeinnonsmallcelllungcancerpatientfollowupofanunexpectedevent AT gelsominofrancesco newdisappearanceofcomplicatedatheromatousplaquesonrechallengewithpd1pdl1axisblockadeinnonsmallcelllungcancerpatientfollowupofanunexpectedevent AT brocchistefano newdisappearanceofcomplicatedatheromatousplaquesonrechallengewithpd1pdl1axisblockadeinnonsmallcelllungcancerpatientfollowupofanunexpectedevent AT poerioantonio newdisappearanceofcomplicatedatheromatousplaquesonrechallengewithpd1pdl1axisblockadeinnonsmallcelllungcancerpatientfollowupofanunexpectedevent AT melottibarbara newdisappearanceofcomplicatedatheromatousplaquesonrechallengewithpd1pdl1axisblockadeinnonsmallcelllungcancerpatientfollowupofanunexpectedevent AT sperandifrancesca newdisappearanceofcomplicatedatheromatousplaquesonrechallengewithpd1pdl1axisblockadeinnonsmallcelllungcancerpatientfollowupofanunexpectedevent AT gargiulomauro newdisappearanceofcomplicatedatheromatousplaquesonrechallengewithpd1pdl1axisblockadeinnonsmallcelllungcancerpatientfollowupofanunexpectedevent AT borghiclaudio newdisappearanceofcomplicatedatheromatousplaquesonrechallengewithpd1pdl1axisblockadeinnonsmallcelllungcancerpatientfollowupofanunexpectedevent AT fiorentinomichelangelo newdisappearanceofcomplicatedatheromatousplaquesonrechallengewithpd1pdl1axisblockadeinnonsmallcelllungcancerpatientfollowupofanunexpectedevent AT ardizzoniandrea newdisappearanceofcomplicatedatheromatousplaquesonrechallengewithpd1pdl1axisblockadeinnonsmallcelllungcancerpatientfollowupofanunexpectedevent |